A fast-moving outbreak, and a case count still finding its feet

Bundibugyo Ebola is spreading faster than the numbers can settle — and there is nothing licensed to stop it.

Armando Cuesta, MD Monday, 8 June 2026 · 2 min read

Analysis. Drafted by The Vital Record’s AI under Armando Cuesta, MD’s direction and reviewed by him before publication. How we label →

Analysis by Armando Cuesta, MD. AI-drafted under his direction.

The headline number is alarming and worth stating plainly: the CDC counts 515 confirmed cases and 91 deaths in the Democratic Republic of the Congo as of June 6, up from 363 on June 2. A jump of that size in four days describes an outbreak that is still accelerating, not one that is being brought under control.

Two things deserve a clinician’s caution before we read too much into any single figure.

First, the count is not yet stable. CIDRAP reports that WHO and CDC sharply revised the official tally downward earlier in this outbreak — from figures approaching 1,000 to a few hundred — as suspected cases were reclassified against laboratory confirmation. The current numbers reflect that tighter case definition, which is the right way to count. But it also means denominators are still moving. As of June 5, ECDC listed 381 confirmed cases and 64 deaths in DRC; CDC listed 515 and 91 a day later. Those are not contradictions so much as the normal lag between surveillance systems mid-outbreak. Trend matters more than any one day’s number, and the trend is upward.

Second, and this is the part with no asterisk: there is no licensed countermeasure. The CDC states flatly that “there is no vaccine for Bundibugyo virus, and treatment consists of supportive care.” The MMWR field report (mm7522e3) is equally direct — “no medications or vaccines against BVD have been approved.” The vaccines and monoclonal antibodies developed for Zaire ebolavirus are not established for this species.

An outbreak that is accelerating, with no approved vaccine or therapeutic, is contained by epidemiology — contact tracing, isolation, safe care — not by a syringe.

What we still do not know: whether the four-day rise reflects true acceleration or improved case-finding catching up to existing spread; the current case-fatality ratio once reporting stabilizes (prior Bundibugyo outbreaks ranged from 25% in Uganda in 2007 to 50% in DRC in 2012, per CDC); and how durably Uganda’s 19 cases — some locally acquired — can be held. ECDC assesses the risk to people in the EU/EEA as very low. That assessment, for now, is the steady part of the picture.

Trials Today

Phase 3 VENTURA-5 (aticaprant, J&J) — NCT06635135 — TERMINATED, results posted; relapse-prevention arm of the discontinued VENTURA depression program (only 47 enrolled).

Phase 3 HYPERION (sotatercept/WINREVAIR, Merck) — NCT04811092 — TERMINATED by design (Amendment 11) to move newly diagnosed PAH patients onto the approved drug — not a safety or futility stop.

Phase 3 LoTam / Alliance A012301 (low-dose tamoxifen) — NCT06671912 — SUSPENDED; ~1,556 planned in molecular low-risk early breast cancer. No reason given in the registry.

At the Agencies

FDA approval — vepdegestrant (VEPPANU), first PROTAC degrader — Cleared for ESR1-mutant ER+/HER2- advanced breast cancer; label confined to the ESR1-mutant subgroup (VERITAC-2).

EMA CHMP positive opinion — camizestrant (Etcamah) — 18-21 May 2026 meeting; recommends EU authorisation in ESR1-mutant ER+/HER2- breast cancer (also Jascayd/nerandomilast, oral Wegovy) — a recommendation, not a final marketing authorisation.

FDA Early Alert — Insulet Omnipod cannula tear — Potentially high-risk: cannula tear can cause silent insulin under-delivery with no Pod alert; certain Pod lots recalled (24 serious injuries, no deaths as of May 20, 2026).